Analyst consensus rating
Krystal Biotech Analyst Rating: Strong Buy
Direct answer
Krystal Biotech's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $395.44.
Forecast evidence checked October 27, 2026.
Get free Krystal Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $320.58
- Average price target
- $395.44
- High price target
- $474.00
- Low price target
- $284.00
- Low target gap
- -11.4%
- Target upside
- +23.4%
- High target gap
- +47.9%
- Target range width
- 59.3%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Krystal Biotech?
Krystal Biotech has a verified Strong Buy consensus. The same dataset has an average price target of $395.44.
How far are Krystal Biotech's low and high targets from the recorded price?
The low target implies -11.4%, while the high target implies +47.9%.
How many analysts are included in Krystal Biotech's consensus?
The verified consensus includes 9 analysts.
How is Krystal Biotech's target upside or downside calculated?
The average target of $395.44 is divided by the recorded price of $320.58, then one is subtracted to produce +23.4%. This does not guarantee a future return.
When was Krystal Biotech's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.